PE20241385A1 - Formulaciones de radiprodil - Google Patents
Formulaciones de radiprodilInfo
- Publication number
- PE20241385A1 PE20241385A1 PE2024000212A PE2024000212A PE20241385A1 PE 20241385 A1 PE20241385 A1 PE 20241385A1 PE 2024000212 A PE2024000212 A PE 2024000212A PE 2024000212 A PE2024000212 A PE 2024000212A PE 20241385 A1 PE20241385 A1 PE 20241385A1
- Authority
- PE
- Peru
- Prior art keywords
- radiprodil
- formulations
- compound
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230331P | 2021-08-06 | 2021-08-06 | |
| PCT/US2022/039543 WO2023014956A1 (en) | 2021-08-06 | 2022-08-05 | Formulations of radiprodil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241385A1 true PE20241385A1 (es) | 2024-07-09 |
Family
ID=83189017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000212A PE20241385A1 (es) | 2021-08-06 | 2022-08-05 | Formulaciones de radiprodil |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250127770A1 (https=) |
| EP (1) | EP4380547A1 (https=) |
| JP (1) | JP2024529185A (https=) |
| KR (1) | KR20240052765A (https=) |
| CN (1) | CN118019521A (https=) |
| AU (1) | AU2022323381A1 (https=) |
| CA (1) | CA3228004A1 (https=) |
| CO (1) | CO2024002715A2 (https=) |
| IL (1) | IL310652A (https=) |
| MX (1) | MX2024001744A (https=) |
| PE (1) | PE20241385A1 (https=) |
| WO (1) | WO2023014956A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137652A2 (en) * | 2023-12-20 | 2025-06-26 | Grin Therapeutics, Inc. | Methods of using radiprodil in the treatment of disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2453383C (en) | 2001-07-24 | 2010-04-06 | Richter Gedeon Vegyeszeti Gyar Rt | Piperidine derivatives as nmda receptor antagonists |
| CA2730253A1 (en) * | 2008-07-08 | 2010-01-14 | Alphonso Higuera | Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide |
| AU2009282822A1 (en) * | 2008-08-21 | 2010-02-25 | Richter Gedeon Nyrt. | Methods for treating CNS disorders |
| HUP0900130A3 (en) * | 2009-03-03 | 2012-02-28 | Richter Gedeon Nyrt | Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation |
| US8328687B2 (en) | 2010-07-09 | 2012-12-11 | Ford Global Technologies, Llc | Method for controlling an engine that may be automatically stopped |
-
2022
- 2022-08-05 CA CA3228004A patent/CA3228004A1/en active Pending
- 2022-08-05 CN CN202280060141.5A patent/CN118019521A/zh active Pending
- 2022-08-05 US US18/681,382 patent/US20250127770A1/en active Pending
- 2022-08-05 EP EP22764500.9A patent/EP4380547A1/en active Pending
- 2022-08-05 AU AU2022323381A patent/AU2022323381A1/en active Pending
- 2022-08-05 KR KR1020247007585A patent/KR20240052765A/ko active Pending
- 2022-08-05 IL IL310652A patent/IL310652A/en unknown
- 2022-08-05 MX MX2024001744A patent/MX2024001744A/es unknown
- 2022-08-05 WO PCT/US2022/039543 patent/WO2023014956A1/en not_active Ceased
- 2022-08-05 JP JP2024532367A patent/JP2024529185A/ja active Pending
- 2022-08-05 PE PE2024000212A patent/PE20241385A1/es unknown
-
2024
- 2024-03-04 CO CONC2024/0002715A patent/CO2024002715A2/es unknown
-
2025
- 2025-10-31 US US19/376,486 patent/US20260053786A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024002715A2 (es) | 2024-05-20 |
| IL310652A (en) | 2024-04-01 |
| US20250127770A1 (en) | 2025-04-24 |
| WO2023014956A1 (en) | 2023-02-09 |
| AU2022323381A1 (en) | 2024-03-21 |
| JP2024529185A (ja) | 2024-08-01 |
| KR20240052765A (ko) | 2024-04-23 |
| EP4380547A1 (en) | 2024-06-12 |
| US20260053786A1 (en) | 2026-02-26 |
| CA3228004A1 (en) | 2023-02-09 |
| WO2023014956A9 (en) | 2023-12-14 |
| CN118019521A (zh) | 2024-05-10 |
| MX2024001744A (es) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP078023A (es) | Ingrediente farmacéutico activo en base a canabinoide | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CO6241104A2 (es) | "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp" | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
| ECSP12011958A (es) | Composiciones farmacéuticas que comprenden ligandos de receptores sigma | |
| MX2009001660A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis. | |
| MX2024014628A (es) | Compuesto para inhibir o degradar bcl6 y uso de este en farmacia | |
| CL2022001337A1 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| BR112022007207A2 (pt) | Composição farmacêutica que compreende selexipag | |
| ZA202204907B (en) | Orally disintegrating pharmaceutical compositions of apixaban | |
| AR074309A1 (es) | Compuestos anti-inflamatorios y sus composiciones farmaceuticas, dentifricas y adhesivas. metodo | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| PE20241385A1 (es) | Formulaciones de radiprodil | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| AR133241A1 (es) | Compuestos, composiciones y métodos | |
| CL2021001621A1 (es) | Formulaciones orales de branaplam | |
| CO2024009774A2 (es) | Composiciones que contienen fexofenadina | |
| MX2022002022A (es) | Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones. | |
| AR132166A1 (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| AR131625A1 (es) | Compuestos, composiciones y métodos de uso para tratar el hipoparatiroidismo y la osteoporosis | |
| ECSP099733A (es) | Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias |